In ovarian cancer, we have demonstrated that both ROR1 and ROR2 are overexpressed in large cohorts of tumour tissue26, and that silencing ROR1 and ROR2 inhibits metastatic potential26, which supported the oncogenic role of the two receptors. This evidence concerns the gene ROR1 and ovarian carcinoma.